Listed molecular diagnostics biotech Genetic Signatures had secured interest for a $30 million equity raising by Monday evening, after sending out stockbrokers Bell Potter and Taylor Collison to drum up fresh funds.
Genetic Signatures CEO John Melki with co-founder of fund manager Maple-Brown Abbott, Chris Abbott, who is a major shareholder through his private investment firm. Louise Kennerley
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
